FIELD: medicine; oncology.
SUBSTANCE: group of inventions relates to the field of medicine, namely to oncology; it is intended for the treatment of cancer. A pharmaceutical composition for the treatment of cancer contains liposome, while liposome contains: (i) a set of lipids; (ii) a weakly basic antitumor compound and (iii) oxalic acid, oxalic acid salt, tartaric acid or tartaric acid salt. The mass ratio of the set of lipids and the weakly basic antitumor compound ranges from 20:1 to 100:1. A method for obtaining the specified pharmaceutical composition is also presented, including mixing a solution containing the weakly basic antitumor compound with a suspension containing a set of liposomes and oxalic acid, oxalic acid salt, tartaric acid or tartaric acid salt. In addition, a kit for the specified pharmaceutical composition is provided.
EFFECT: use of the group of inventions makes it possible to improve a release profile of an antitumor compound depending on pH, chemical and physical stability, as well as to increase the efficiency and attractiveness of the system for preparing the specified composition.
27 cl, 23 dwg, 38 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD AND COMPOSITION FOR TREATING CANCER | 2011 |
|
RU2541100C2 |
| LIPOSOMAL COMPOSITIONS USED FOR DRUG DELIVERY | 2015 |
|
RU2757110C2 |
| LIPOSOMAL COMPOSITIONS APPLICABLE FOR DRUG DELIVERY | 2005 |
|
RU2574926C2 |
| LIPOSOME HAVING INNER AQUEOUS PHASE AND CONTAINING SULPHOBUTYL ESTER CYCLODEXTRIN SALT | 2010 |
|
RU2575793C2 |
| IMPROVED LIPOSOMES AND THEIR APPLICATION | 2008 |
|
RU2482837C2 |
| LIPOSOMAL PHARMACEUTICAL PREPARATION AND METHOD FOR PREPARING IT | 2007 |
|
RU2494729C2 |
| LIPOSOMAL COMPOSITION | 2010 |
|
RU2476216C1 |
| LIPOSOMAL COMPOSITION AND PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2734900C1 |
| COMBINATION LIPOSOMAL COMPOSITIONS FOR CANCER TREATMENT | 2012 |
|
RU2640934C2 |
| TUMOUR TREATMENT AGENT AND KIT CONTAINING LIPOSOMAL GEMCITABINE COMPOSITION | 2016 |
|
RU2761620C2 |
